15-Strain Therapy Matches FMT for C. diff UK Trial

A randomised phase 1b clinical trial has found that a 15-strain live biotherapeutic product, known as MTC01, performed comparably to a same-donor faecal microbiota transplant (FMT) in treating recurrent Clostridioides difficile infection. Published on 2 June 2026 via Nature.com and led by researchers including Lukas Bethlehem, Jeremiah J. Faith, and Ari Grinspan, the study reports similar efficacy and microbial engraftment between the two treatments, representing a significant step forward in gut microbiome therapeutics.

Why This Matters

Recurrent Clostridioides difficile infection is a serious and debilitating condition affecting the gut microbiome, causing repeated bouts of severe diarrhoea and, in some cases, life-threatening complications. FMT — the transfer of donor stool to restore healthy gut bacteria — has emerged as an effective treatment, but faces practical and regulatory hurdles around standardisation and safety screening. Across the UK, NHS gut health services and microbiome UK researchers have highlighted the need for defined, reproducible alternatives to whole-donor FMT. MTC01, derived from the same donor as the FMT used in the trial, offered a precisely characterised option with comparable outcomes.

Trial Findings: Engraftment and Efficacy Align

The single-blind, parallel-group, phase 1b trial compared FMT directly with MTC01 across two treatment arms, according to the research team. The study found similar rates of efficacy — meaning successful resolution of recurrent infection — alongside comparable microbial engraftment, the process by which introduced bacterial strains colonise and establish themselves within the recipient's gut microbiome. Researchers including Graham J. Britton, Varun Aggarwala, and Ilaria Mogno contributed to the analysis, per the Nature.com publication. The trial's findings suggest that a defined 15-strain product can replicate key microbiome restoration outcomes previously attributed only to complex whole-stool transplants.

What This Means for Gut Health in the UK

For health-conscious adults and clinicians in the UK seeking to improve gut health naturally through evidence-based approaches, this research signals a meaningful shift. A standardised biotherapeutic product could eventually offer a safer, more scalable route to microbiome restoration than donor-dependent FMT, potentially supporting future NHS gut health pathways. The gut-brain connection is also relevant here — restoring a disrupted microbiome has implications beyond digestion, including mood, cognition, and immune regulation, areas of active UK microbiome research at institutions such as King's College London and the University of Reading.

The phase 1b results indicate that moving toward defined, multi-strain live biotherapeutics is scientifically feasible, according to the research team. Further trials will be needed to confirm these findings at larger scale and across broader patient populations before any clinical rollout within NHS pathways could be considered.

You might also like

• The Oral Microbiome: Your Biggest Questions Answered
• Medications May Permanently Alter Gut Microbiome
• How to Improve Your Oral & Gut Health in 6 Steps

96 Bacterial Strains. Two Shots a Day.

GOODIE is an award-winning fermented drink with 96 live bacterial strains — more than any yogurt or kombucha — never pasteurised, clinically tested, and 8 in 10 users felt less bloating within 14 days. Curious?

Find out more →